RISDIPLAM
risdiplam 750 microgram/mL powder for oral liquid, 80 mL
RISDIPLAM (12943F)
12943F
Manner of administration:Oral
Restriction
Indication: Spinal muscular atrophy (SMA)
Treatment phase: Initial treatment occurring after onasemnogene abeparvovec therapy in a patient with
Type 1 SMA
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 0 | DPMQ: $10,841.89 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Evrysdi | |||||